Promising new combo aims to wipe out leukemia cells more effectively

NCT ID NCT07228273

Recruiting now Disease control Sponsor: OHSU Knight Cancer Institute Source: ClinicalTrials.gov ↗

First seen Jun 25, 2026 · Last updated Jul 14, 2026 · Updated 3 times

Summary

This phase 2 trial is testing whether adding the targeted drug venetoclax to a standard chemotherapy regimen (FLAG IDA) works better than the usual treatment for adults newly diagnosed with acute myeloid leukemia (AML). About 102 participants will receive either the new combination or standard care. The main goal is to see if the new combo leads to a deeper remission, where no cancer cells can be detected by sensitive tests.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: venetoclax
What this could lead to: If successful, this could offer a more effective initial treatment for acute myeloid leukemia, potentially leading to deeper remissions and better long-term outcomes.
What could go wrong: This is a phase 2 trial with only 102 participants, so results are preliminary. The combination therapy may cause more side effects than standard care, and it is not yet known if it will improve survival.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ACUTE MYELOID LEUKEMIA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

acute myeloid leukemia myelodysplastic syndrome myelodysplastic syndrome with excess blasts-2 Myelodysplastic Syndromes

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

ACUTE MYELOID LEUKEMIA MYELODYSPLASTIC SYNDROME

Contacts and locations

Locations

OHSU Knight Cancer Institute
RECRUITING

Portland, Oregon, 97239, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.